Literature DB >> 20409979

Exercise hypertension: an adverse prognosis?

Ryan G Smith1, Stanley A Rubin, Myrvin H Ellestad.   

Abstract

We sought to clarify the prognostic importance of an "exaggerated" or "hypertensive" systolic blood pressure response to exercise during an exercise test. Studies evaluating the prognosis for cardiovascular events and cardiovascular mortality in those with hypertension during exercise testing were systematically reviewed. Fourteen studies were identified. Six studies were of healthy volunteers or hypertensives. Eight studies were in subjects with known or suspected heart disease. Without established heart disease, exercise hypertension predicted cardiovascular events and cardiovascular death. However, two of the six studies included a multivariate analysis; both demonstrated no independent association. Studies in subjects with known or suspected heart disease demonstrated that exercise hypertension predicted fewer cardiac events and lesser mortality or, after multivariate adjustment, no associated risk. In a healthy population, a higher exercise blood pressure may indicate hypertension or prehypertension, instead of normal vascular function, and an associated long-term adverse prognosis. In a population with a high burden of heart disease, the highest risk subjects with the most extensive cardiac disease may not be capable of generating pressure or workload to allow the manifestation of exercise systolic hypertension. By comparison, therefore, those with exercise hypertension have a better prognosis.

Entities:  

Year:  2009        PMID: 20409979     DOI: 10.1016/j.jash.2009.10.003

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  2 in total

1.  The blood pressure response to vasodilator stress does not provide independent prognostic information.

Authors:  Eliana Reyes; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2016-08-29       Impact factor: 5.952

2.  Exercise Hypertension in Athletes.

Authors:  Karsten Keller; Katharina Hartung; Luis Del Castillo Carillo; Julia Treiber; Florian Stock; Chantal Schröder; Florian Hugenschmidt; Birgit Friedmann-Bette
Journal:  J Clin Med       Date:  2022-08-19       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.